Simulations Plus to Join Altaris in $375M Acquisition Deal
RESEARCH TRIANGLE PARK, N.C., June 16, 2026 Simulations Plus, a global leader in model-informed and AI-accelerated drug development software,...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
RESEARCH TRIANGLE PARK, N.C., June 16, 2026 Simulations Plus, a global leader in model-informed and AI-accelerated drug development software,...
SOUTH SAN FRANCISCO, California, May 27, 2026 Human Longevity, Inc. (HLI) has announced the creation of Human Life Foundation...
Tel Aviv, Israel & Tokyo, Japan | April 9, 2026 Imagene AI has announced a strategic collaboration with Daiichi...
BOSTON, Massachusetts, United States, April 7, 2026 Alloy Therapeutics Inc. announced a multi-target collaboration and license agreement with Biogen...
